This led to a further revision being made to the NICE guidance at the end of March 2011, which recommended AChE inhibitors for patients with mild to moderate Alzheimer’s disease and memantine for patients with moderate to severe Alzheimer’s disease or who could not tolerate AChE inhibitors [11]. This evidence concerns the gene ACHE and Alzheimer disease.